Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging.
Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging.
复制标题
DOI：
10.1186/s41479-018-0048-3
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Ferreira DM
中科院分区：
文献类型：
--
作者：
German EL;Al-Hakim B;Mitsi E;Pennington SH;Gritzfeld JF;Hyder-Wright AD;Banyard A;Gordon SB;Collins AM;Ferreira DM
社区获得性肺炎和下呼吸道感染的发病率在晚年显著上升。已知肺炎球菌荚膜多糖的免疫球蛋白M（IgM）抗体水平会随着年龄的增长而下降;然而，肺炎球菌蛋白的IgM抗体水平是否也会下降尚未研究。本研究测量了从年龄< 60岁和≥ 60岁的医院患者中分离的肺炎球菌表面蛋白A（PspA）和未包囊肺炎球菌菌株的血清中特异性IgM抗体的血清水平和结合能力，这些患者有和没有下呼吸道感染。一组年轻的健康志愿者被用作对照，代表肺炎球菌肺炎风险极低的成年人。通过酶联免疫吸附试验（ELISA）测定IgM血清抗体水平，并进行流式细胞术以评估IgM结合能力。采用线性回归和单因素方差分析（ANOVA）检验对结果进行分析。PspA和未包囊肺炎球菌菌株的IgM抗体水平和结合能力随年龄变化。这些研究结果表明，蛋白质为基础的肺炎球菌疫苗可以提供保护性免疫的老年人。LRTI试验（LRTI和对照组）于2013年10月获得国家卫生服务研究伦理委员会的批准（12/NW/0713）。征聘工作于2013年1月开始，于2013年7月完成。从EHPC剂量范围和重现性试验中采集健康志愿者样本，该试验于2011年10月获得同一研究伦理委员会批准（11/NW/0592）。本研究的招募时间为2011年10月至2012年12月。LRTI试验：（NCT 01861184），EHPC剂量范围和重现性试验：（ISRCTN 85403723）。
The incidence of community-acquired pneumonia and lower respiratory tract infection rises considerably in later life. Immunoglobulin M (IgM) antibody levels to pneumococcal capsular polysaccharide are known to decrease with age; however, whether levels of IgM antibody to pneumococcal proteins are subject to the same decline has not yet been investigated. This study measured serum levels and binding capacity of IgM antibody specific to the pneumococcal surface protein A (PspA) and an unencapsulated pneumococcal strain in serum isolated from hospital patients aged < 60 and ≥ 60, with and without lower respiratory tract infection. A group of young healthy volunteers was used as a comparator to represent adults at very low risk of pneumococcal pneumonia. IgM serum antibody levels were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry was performed to assess IgM binding capacity. Linear regression and one-way analysis of variance (ANOVA) tests were used to analyse the results. Levels and binding capacity of IgM antibody to PspA and the unencapsulated pneumococcal strain were unchanged with age. These findings suggest that protein-based pneumococcal vaccines may provide protective immunity in the elderly. The LRTI trial (LRTI and control groups) was approved by the National Health Service Research Ethics Committee in October 2013 (12/NW/0713). Recruitment opened in January 2013 and was completed in July 2013. Healthy volunteer samples were taken from the EHPC dose-ranging and reproducibility trial, approved by the same Research Ethics Committee in October 2011 (11/NW/0592). Recruitment for this study ran from October 2011 until December 2012. LRTI trial: (NCT01861184), EHPC dose-ranging and reproducibility trial: (ISRCTN85403723).
登录
查看更多内容
影响因子：
6.4
作者：
Leggat, David J.;Thompson, Rebecca S.;Westerink, M. A. Julie
通讯作者：
Westerink, M. A. Julie
影响因子：
10
作者：
Ewig, S.;Birkner, N.;Hoeffken, G.
通讯作者：
Hoeffken, G.
影响因子：
4.6
作者：
Baxendale, H. E.;Johnson, M.;Goldblatt, D.
通讯作者：
Goldblatt, D.
影响因子：
3.1
作者：
CRAIN, MJ;WALTMAN, WD;BRILES, DE
通讯作者：
BRILES, DE
DOI：
10.1164/ajrccm.163.4.9909121
发表时间：
2001-03-01
影响因子：
24.7
作者：
Ho, JC;Chan, KN;Tsang, KW
通讯作者：
Tsang, KW